Recent advances in personalized colorectal cancer research

Cancer Letters

Volumn 347, Issue 1, 2014, Pages 15-21

  Kraus, Sarah ^a,b   Nabiochtchikov, Ilana ^a,b   Shapira, Shiran ^a,b   Arber, Nadir ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Biomarkers; Colorectal cancer (CRC); Epigenetic markers; KRAS; Monoclonal antibodies (mAbs); Oncotype

Indexed keywords

B RAF KINASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD24 ANTIGEN; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR MARKER;

B RAF KINASE GENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; COLORECTAL ADENOMA; COLORECTAL CANCER; DIAGNOSTIC TEST; EPIGENETICS; GENE AMPLIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; HER2 GENE; HUMAN; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOTYPE DX ASSAY; PERSONALIZED MEDICINE; PHOSPHATIDYLINOSITOL 3 KINASE GENE; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY;

BIOMARKERS; COLORECTAL CANCER (CRC); EPIGENETIC MARKERS; KRAS; MONOCLONAL ANTIBODIES (MABS); ONCOTYPE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; GENES, ERBB-2; GENES, RAS; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 84897054309     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.025     Document Type: Review

References (67)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63(2013):11-30.
2. National Cancer Institute. SEER Stat Fact Sheets: Colon and Rectum, 2012; http://seer.cancer.gov/statfacts/html/colorect.html.
3. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
4. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A., Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9:962-972.
5. National Comprehensive Cancer Network, Colon Cancer. NCCN Clinical Practice Guidelines in, Oncology, 2009; http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
6. Wang G., Kelley R.K. Gappnet KRAS mutational analysis for colorectal cancer: application pharmacogenomic. PLoS Curr. 2010, 2.
7. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
8. Andreyev H.J., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl. Cancer Inst. 1998, 90:675-684.
9. Bazan V., Agnese V., Corsale S., Calò V., Valerio M.R., Latteri M.A., Vieni S., Grassi N., Cicero G., Dardanoni G., Tomasino R.M., Colucci G., Gebbia N., Russo A. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann. Oncol. 2005, 16(Suppl. 4):50-55. Gruppo Oncologico dell'Italia Meridionale (GOIM).
10. Normanno N., Tejpar S., Morgillo F., De Luca A., Van Cutsem E., Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 2009, 6:519-527.
11. Etienne-Grimaldi M.C., Formento J.L., Francoual M., François E., Formento P., Renée N., Laurent-Puig P., Chazal M., Benchimol D., Delpero J.R., Letoublon C., Pezet D., Seitz J.F., Milano G. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res. 2008, 14:4830-4835.
12. Hurwitz H.I., Yi J., Ince W., Novotny W.F., Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22-28.
13. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
14. De Roock W., De Vriendt V., Normanno N., Ciardiello F., Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011, 12:594-603.
15. Vaughn C.P., Zobell S.D., Furtado L.V., Baker C.L., Samowitz W.S. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chrom. Cancer 2011, 50:307-312.
16. Irahara N., Baba Y., Nosho K., Shima K., Yan L., Dias-Santagata D., Iafrate A.J., Fuchs C.S., Haigis K.M., Ogino S. NRAS mutations are rare in colorectal cancer. Diagn. Mol. Pathol. 2010, 19:157-163.
17. Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., Carneiro F., Oliveira C., Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255.
18. Zhang J., Roberts T.M., Shivdasani R.A. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 2011, 141:50-61.
19. Liao X., Morikawa T., Lochhead P., Imamura Y., Kuchiba A., Yamauchi M., Nosho K., Qian Z.R., Nishihara R., Meyerhardt J.A., Fuchs C.S., Ogino S. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin. Cancer Res. 2012, 18:2257-2268.
20. Agarwal A., Das K., Lerner N., Sathe S., Cicek M., Casey G., Sizemore N. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene. 2005, 24:1021-1031.
21. Fang D., Hawke D., Zheng Y., Xia Y., Meisenhelder J., Nika H., Mills G.B., Kobayashi R., Hunter T., Lu Z. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J. Biol. Chem. 2007, 282:11221-11229.
22. Kaur J., Sanyal S.N. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol. 2010, 31:623-631.
23. Liao X., Lochhead P., Nishihara R., Morikawa T., Kuchiba A., Yamauchi M., Imamura Y., Qian Z.R., Baba Y., Shima K., Sun R., Nosho K., Meyerhardt J.A., Giovannucci E., Fuchs C.S., Chan A.T., Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 2012, 367:1596-1606.
24. Domingo E., Church D.N., Sieber O., Ramamoorthy R., Yanagisawa Y., Johnstone E., Davidson B., Kerr D.J., Tomlinson I.P., Midgley R. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 2013, 31:4297-4305.
25. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
26. Nishihara R., Lochhead P., Kuchiba A., Jung S., Yamauchi M., Liao X., Imamura Y., Qian Z.R., Morikawa T., Wang M., Spiegelman D., Cho E., Giovannucci E., Fuchs C.S., Chan A.T., Ogino S. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013, 309:2563-2571.
27. Chagpar R., Chiang Y.J., Xing Y., Cormier J.N., Feig B.W., Rashid A., Chang G.J., You Y.N. Neuroendocrine tumors of the colo and rectum: prognostic relevance and comparative performance of current staging systems. Ann. Surg. Oncol. 2013, 20:1170-1178.
28. Kelley R.K., Vennok A.P. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?. Clin. Colorectal. Cancer 2011, 10:73-80.
29. Agesen T.H., Sveen A., Merok M.A., Lind G.E., Nesbakken A., Skotheim R.I., Lothe R.A. ColoGuideEX: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012, 61:1560-1567.
30. Gray R.G., Quirke P., Handley K., Lopatin M., Magill L., Baehner F.L., Beaumont C., Clark-Langone K.M., Yoshizawa C.N., Lee M., Watson D., Shak S., Kerr D.J. Validationstudyof aquantitativemultigenereversetranscriptase polymerase chain reaction for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. 2011, 29:4611-4619.
31. Genomic Health. Press release Genomic Health's Oncotype DX® Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients. May 14, 2009. Available at: http://investor.genomichealth.com/releasedetail.cfm?ReleaseID=384226.
32. Goldstein T., Paull E.O., Ellis M.J., Stuart J.M. Molecular pathways: Extracting medical knowledge from high throughput genomic data. Clin. Cancer Res. 2013, 19:3114-3120.
33. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Corà D., Di Nicolantonio F., Buscarino M., Petti C., Ribero D., Russolillo N., Muratore A., Massucco P., Pisacane A., Molinaro L., Valtorta E., Sartore-Bianchi A., Risio M., Capussotti L., Gambacorta M., Siena S., Medico E., Sapino A., Marsoni S., Comoglio P.M., Bardelli A., Trusolino L. A molecularly annotated platform of patient derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1:508-523.
34. Roepman P., Schlicker A., Tabernero J., Majewski I., Tian S., Moreno V., Snel M.H., Chresta C.M., Rosenberg R., Nitsche U., Macarulla T., Capella G., Salazar R., Orphanides G., Wessels L.F., Bernards R., Simon I.M. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 2013, 134:552-562.
35. Network Cancer.Genome.Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
36. Perez-Villamil B., Romera-Lopez A., Hernandez-Prieto S., Lopez-Campos G., Calles A., Lopez-Asenjo J.A., Sanz-Ortega J., Fernandez-Perez C., Sastre J., Alfonso R., Caldes T., Martin-Sanchez F., Diaz-Rubio E. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012, 12:260.
37. Hundt S., Haug U., Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1935-1953.
38. Fakih M.G., Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006, 20:579-587.
39. Macdonald J.S. Carcinoembryonic antigen screening: pros and cons. Semin. Oncol. 1999, 26:556-560.
40. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin. Chem. 2001, 47:624-630.
41. Fletcher R.H. Carcinoembryonic antigen. Ann. Intern. Med. 1986, 104:66-73.
42. Locker G.Y., Hamilton S., Harris J. ASCO 2006 Update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24(2006):5313-5327.
43. Duffy M.J., van Dalen A., Haglund C., et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur. J. Cancer 2003, 39:718-727.
44. Sagiv E., Memeo L., Karin A., et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006, 131:630-639.
45. Kraus S., Goel A., Arber N. Blood-based peptide, genetic, and epigenetic biomarkers for diagnosing gastrointestinal cancers. Expert Opin. Med. Diagn. 2010, 4:459-471.
46. Goldstein M.J., Mitchell E.P. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005, 23:338-351.
47. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
48. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
49. Nagasaka T., Koi M., Kloor M., et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 2008, 134:1950-1960.
50. Grady W.M., Rajput A., Lutterbaugh J.D., Markowitz S.D. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001, 61:900-902.
51. Leung W.K., To K.F., Man E.P., et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. 2005, 100:2274-2279.
52. Wallner M., Herbst A., Behrens A., et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 2006, 12:7347-7352.
53. Li M., Chen W.D., Papadopoulos N., et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 2009, 27:858-863.
54. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
55. Kim R.Y., Xu H., Myllykangas S., Ji H. Genetic-based biomarkers and next-generation sequencing: the future of personalized care in colorectal cancer. Per. Med. 2011, 8:331-345.
56. Stadler Z.K., Thom P., Robson M.E., et al. Genome-wide association studies of cancer. J. Clin. Oncol. 2010, 28:4255-4267.
57. Garman K.S., Acharya C.R., Edelman E., et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc. Natl Acad. Sci. USA 2008, 105:19432-19437.
58. Garman K.S., Acharya C.R., Edelman E., Grade M., Gaedcke J., Sud S., Barry W., Diehl A.M., Provenzale D., Ginsburg G.S., Ghadimi B.M., Ried T., Nevins J.R., Mukherjee S., Hsu D., Potti A. Retraction for Garman et al.: a genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc. Natl. Acad. Sci. USA 2011, 108.
59. Kraus S., Hummler S., Toriola A.T., Poole E.M., Scherer D., Kotzmann J., Makar K.W., Kazanov D., Galazan L., Naumov I., Coghill A.E., Duggan D., Gigic B., Arber N., Ulrich C.M. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. Pharmacogenet. Genomics 2013, 23:428-437.
60. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355:885-895.
61. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon D.H., Kim K., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355:873-874.
62. Baron J.A., Sandler R.S., Bresalier R.S., Quan H., Riddell R., Lanas A., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 13:1674-1682.
63. Cross J.T., Poole E.M., Ulrich C.M. A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J. 2008, 8:237-247.
64. Poole E.M., Bigler J., Whitton J., Sibert J.G., Kulmacz R.J., Potter J.D., et al. Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis 2007, 28:1259-1263.
65. Slattery M.L., Curtin K., Poole E.M., Duggan D.J., Samowitz W.S., Peters U., et al. Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. Int. J. Cancer J. Int. Cancer 2011, 128:2726-2734.
66. Galbraith R.L., Poole E.M., Duggan D., Muehling J., Hsu L., Makar K., et al. Polymorphisms in WNT6 and WNT10A and colorectal adenoma risk. Nutr. Cancer 2011, 63:558-564.
67. Poole E.M., Hsu L., Xiao L., Kulmacz R.J., Carlson C.S., Rabinovitch P.S., et al. Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol. Biomarkers Prevention 2010, 19:547-557. A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.